NF-κB Signaling: IKK Complex Activation, IκBα Degradation, and Transcriptional Control of Inflammation and Survival

# NF-κB Signaling: IKK Complex Activation, IκBα Degradation, and Transcriptional Control of Inflammation and Survival

For Research Use Only. Not for human or animal therapeutic use.

---

Introduction: Master Regulator of Inflammatory and Survival Gene Programs

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) describes a family of dimeric transcription factors that coordinates the transcriptional response to infection, cellular stress, DNA damage, cytokines, and antigen receptor engagement. NF-κB activity governs expression of hundreds of target genes encoding pro-inflammatory cytokines, chemokines, adhesion molecules, anti-apoptotic proteins, and immunomodulatory factors — making it one of the most broadly influential transcriptional regulators in mammalian biology.

Dysregulated NF-κB is implicated in nearly every inflammatory disease context (rheumatoid arthritis, inflammatory bowel disease, sepsis, atherosclerosis), in cancer (as a survival and therapy-resistance factor in lymphoma, myeloma, breast, lung, and colon carcinomas), and in neurodegeneration (NF-κB activation in microglia and astrocytes amplifies neuroinflammation in Alzheimer's and Parkinson's disease models). Conversely, NF-κB is required for normal immune development — genetic deletion of RelB or NF-κB2/p52 in mice causes profound immunodeficiency.

Two molecularly distinct NF-κB activation pathways exist: the canonical (classical) pathway, driven by IKKβ-mediated IκBα phosphorylation and proteasomal degradation; and the non-canonical (alternative) pathway, driven by NIK-mediated IKKα activation and p100 processing to p52. This article details the architecture of both pathways, the structure and DNA-binding specificity of NF-κB dimers, the kinetics and feedback loops that shape transcriptional responses, and the research tools that selectively interrogate each node.

---

The NF-κB Protein Family

Structural Organization

The mammalian NF-κB family comprises five members, all sharing a ~300-amino-acid N-terminal Rel homology domain (RHD) responsible for dimerization, nuclear localization, IκB binding, and sequence-specific DNA recognition:

All five members can form homo- and heterodimers (theoretically 15 possible combinations), though only ~10 are physiologically abundant. The most common dimer is RelA/p50 (p65/p50), which mediates the canonical transcriptional response. p50/p50 homodimers bind κB sites without a TAD and recruit co-repressors (HDAC1, HDAC3), actively repressing κB-driven genes in the absence of stimulus. RelB/p52 heterodimers are the effectors of non-canonical signaling.

κB DNA Elements

NF-κB dimers recognize 9–11 bp κB consensus sequences (5'-GGGRNNTYCCC-3') in promoter and enhancer regions of target genes. While all dimers recognize overlapping sequences, RHD loop structures confer differential affinity: RelA/p50 prefers GGGACTTTCC; RelB/p52 shows preference for GGGATTTTCC; c-Rel dimers recognize GGGGATTCCC with higher affinity. These subtle differences, combined with surrounding chromatin state, explain how different dimers activate overlapping but non-identical gene programs.

---

Canonical NF-κB Pathway: IKK Complex and IκB Degradation

The IκB Kinase (IKK) Complex

The IKK complex is the convergence point for canonical NF-κB activation. It consists of three core subunits:

• •IKKα (IKK1/CHUK): Catalytic serine/threonine kinase; phosphorylates IκBα at S32/S36 in the canonical pathway; also the effector kinase in the non-canonical pathway
• •IKKβ (IKK2): Catalytic serine/threonine kinase; the primary kinase for IκBα phosphorylation in canonical pathway; more abundant and more active than IKKα in canonical signaling
• •IKKγ (NEMO/NF-κB Essential Modulator): Non-catalytic regulatory scaffold; contains a coiled-coil domain (CC1) and NEMO ubiquitin-binding domain (NUB) essential for ubiquitin-dependent IKK activation

IKK complex architecture: IKKα and IKKβ each contain an N-terminal kinase domain, a leucine zipper (LZ) for heterodimerization, and a helix-loop-helix (HLH) motif. IKKγ/NEMO binds to both IKKα and IKKβ through a C-terminal NEMO-binding domain (NBD) present on both catalytic subunits. The native IKK complex runs at ~700–900 kDa by gel filtration, suggesting multiple copies of each subunit and association with additional regulatory proteins (ELKS, HSP90, Cdc37).

IκB Proteins: Cytoplasmic Anchors of NF-κB

The IκB (inhibitor of κB) family includes IκBα, IκBβ, IκBε, Bcl-3, IκBζ, and the C-terminal ankyrin-repeat domains of p105 and p100. All share multiple ankyrin repeats that mask the nuclear localization signal (NLS) of NF-κB dimers and retain them in the cytoplasm.

IκBα: The primary canonical pathway target; 37 kDa; contains an N-terminal signal-response domain with S32 and S36 (IKK phosphorylation sites), a central ankyrin-repeat domain (6 repeats), and a C-terminal PEST sequence (proline-glutamate-serine-threonine-rich, targeting constitutive turnover). IκBα is also a direct NF-κB target gene — stimulus-induced NF-κB drives NFKBIA transcription, producing new IκBα that re-enters the nucleus to terminate the response (negative feedback loop with ~30–90 min kinetics).

IκBβ: Similar structure to IκBα but lacks equivalent PEST-mediated constitutive turnover; activates more slowly and sustains NF-κB activity longer; does not participate in rapid negative feedback.

IκBε: Delayed kinetics; participates in dampening late-phase NF-κB responses.

The Ubiquitin-Proteasome Cascade

IKKβ phosphorylates IκBα at S32 and S36, creating a phosphodegron recognized by the SCF-β-TrCP ubiquitin E3 ligase complex (SKP1-CUL1-F-box protein β-TrCP1/2). β-TrCP adds K48-linked polyubiquitin chains to K21 and K22 of IκBα, targeting it for 26S proteasomal degradation. This process is rapid (t₁/₂ of phospho-IκBα ~5 min) and complete — NF-κB dimers are released from all IκBα molecules within 10–15 min of strong stimulation (TNFα, LPS, IL-1β).

Upstream Signaling: TNF, IL-1R, TLR, TCR, BCR

TNF receptor (TNFR1): TNFα engagement triggers TNFR1 trimerization and assembly of Complex I: TRADD (adaptor), RIPK1 (RIP1 kinase), TRAF2/5, and cIAP1/2. TRAF2/5 and cIAP1/2 assemble K63-ubiquitin chains on RIPK1; these chains recruit TAB1/2-TAK1 and NEMO-IKK complex, enabling TAK1-mediated IKKβ S177/S181 phosphorylation.

IL-1R/TLR (MyD88 pathway): IL-1β (IL-1R1), LPS (TLR4), and flagellin (TLR5) signal through MyD88/TRIF adaptor proteins → IRAK4 → IRAK1 → TRAF6 → TAK1 → IKKβ. IRAK4 is the master kinase for TLR/IL-1R signaling and a validated drug target (IRAK4 inhibitors in clinical development for inflammatory disease).

T cell receptor (TCR): TCR engagement activates PKCθ → CARD11-BCL10-MALT1 (CBM complex) → TRAF6/TRAF2 → TAK1 → IKK.

B cell receptor (BCR): BCR signaling activates PKCβ → CARD11-BCL10-MALT1 → IKK; MALT1 is a paracaspase whose proteolytic activity (cleaving A20, CYLD, RELB, BCL10) amplifies NF-κB activation.

Genotoxic stress: DNA double-strand breaks activate ATM → NEMO/IKKγ SUMOylation in the nucleus → nuclear export → TRAF6-dependent IKK activation; this mechanism couples DNA damage sensing to NF-κB-dependent survival signaling.

---

Non-Canonical NF-κB Pathway: NIK and p100 Processing

NIK: NF-κB-Inducing Kinase

The non-canonical pathway is activated by a subset of TNFR superfamily members: BAFF-R, CD40, LTβR, TWEAK-R (Fn14), RANK, and CD27. These receptors signal through TRAF3 and TRAF2, which in resting cells form a constitutive degradation complex targeting NIK (MAP3K14) for continuous proteasomal turnover: TRAF3-TRAF2-cIAP1/2 → K48-ubiquitin on NIK → basal NIK degradation.

Upon ligand binding, receptor-bound TRAF3 and TRAF2 are themselves ubiquitinated and degraded. This removes the NIK degradation machinery, allowing NIK protein to accumulate. Stabilized NIK phosphorylates and activates IKKα (without IKKβ or NEMO involvement), and IKKα phosphorylates p100 at S866/S870 in its C-terminal inhibitory domain, creating a β-TrCP recognition motif.

p100 Processing to p52

β-TrCP ubiquitinates phospho-p100, but rather than complete proteasomal degradation, the 26S proteasome processively degrades only the C-terminal ankyrin-repeat "IκB-like" domain, generating p52. The p52/RelB heterodimer is the primary non-canonical NF-κB effector; it accumulates in the nucleus with slow kinetics (hours to days vs. minutes for canonical) and activates a distinct gene program: CXCL13, CCL19, CCL21, BAFF (TNFSF13B), APRIL (TNFSF13), LTβ, and genes required for secondary lymphoid organ organogenesis.

Biological Roles of Non-Canonical Signaling

Non-canonical NF-κB is critical for:

• •B cell survival and maturation: BAFF/BAFF-R → NIK → p52/RelB → BAFF and anti-apoptotic genes maintain mature B cell pool
• •Secondary lymphoid organ development: LTβR → NIK → p52/RelB → stromal chemokine program (CXCL13, CCL19/21) drives lymph node and spleen architecture
• •Dendritic cell differentiation: CD40L → NIK → RelB/p52 programs DC maturation and immunostimulatory capacity
• •Osteoclastogenesis: RANKL → RANK → TRAF6/NIK → both canonical (TRAF6-TAK1-IKKβ) and non-canonical (NIK-IKKα-p100→p52) → NFATc1 costimulation

---

NF-κB Target Genes and Transcriptional Programs

Pro-Inflammatory Cytokine and Chemokine Program

Direct NF-κB targets with κB sites in their promoters/enhancers include:

Cytokines: TNF, IL-6, IL-1β, IL-12B (p40 subunit), IL-8/CXCL8, GM-CSF/CSF2, IFN-β (together with IRF3)

Chemokines: CXCL1, CXCL2, CXCL8, CCL2 (MCP-1), CCL5 (RANTES), CXCL10 (IP-10)

Adhesion molecules: ICAM-1/ICAM1, VCAM-1/VCAM1, E-selectin/SELE — critical for leukocyte recruitment to sites of inflammation

Enzymes: COX-2/PTGS2, iNOS/NOS2, MMP-1, MMP-2, MMP-9, MMP-13

Anti-Apoptotic Survival Program

NF-κB was identified as a survival factor through its ability to suppress TNFα-induced apoptosis. Key anti-apoptotic targets:

• •BCL-2 family: BCL2, BCL-XL/BCL2L1, BFL-1/A1/BCL2A1 — mitochondrial outer membrane stabilization
• •IAP family: cIAP1/BIRC2, cIAP2/BIRC3, XIAP/BIRC4, survivin/BIRC5 — caspase inhibitors
• •FLIP: CFLAR (c-FLIP) — catalytically inactive caspase-8 homolog; blocks death receptor-induced apoptosis by competing with procaspase-8 for DISC incorporation
• •Mn-SOD: SOD2 — mitochondrial antioxidant; reduces ROS-mediated pro-apoptotic signaling

Cell Cycle and Proliferation Program

• •CCND1 (Cyclin D1): Promotes G1-S transition; NF-κB-driven Cyclin D1 is a key oncogenic mechanism in B-cell lymphomas
• •MYC: NF-κB directly activates c-MYC transcription in B cells; cooperates with Wnt/β-catenin
• •CDC25A: Dual-specificity phosphatase; activates CDK2; accelerates S-phase entry

Feedback and Regulatory Program

• •NFKBIA (IκBα): Rapid negative feedback (~30–60 min); quantitative dynamics model of NF-κB oscillations depends on IκBα re-synthesis rate
• •NFKBIE (IκBε): Delayed feedback (~2–4 h)
• •TNFAIP3 (A20): Deubiquitinase (removes K63 chains from RIPK1, TRAF6) AND ubiquitin E3 ligase (applies K48 chains); dual mechanism terminates upstream IKK activation; A20 is a tumor suppressor lost in multiple B-cell lymphoma subtypes
• •CYLD: Deubiquitinase targeting K63 chains on RIPK1, TRAF2; CYLD loss drives constitutive NF-κB in cylindromatosis and certain lymphomas

---

Regulatory Mechanisms: Post-Translational Modifications of RelA

RelA/p65 transcriptional activity is extensively regulated by post-translational modifications beyond IκBα-mediated cytoplasmic retention:

Phosphorylation:

• •S276 (PKAc, MSK1): Promotes interaction with CBP/p300; enables p50/p65 to replace p50/p50 repressive dimers on κB sites
• •S311 (PKCζ): Required for CBP recruitment; phosphorylated by oxidative stress
• •S468 (IKKε/TBK1, GSK3β): Modulates nuclear import/export and target gene selectivity
• •S536 (IKKβ, RSK1): Cytoplasmic phosphorylation promoting nuclear import; also affects transactivation in the nucleus

Acetylation:

• •K310 (p300/CBP): Required for full transcriptional activity; SIRT1 and SIRT2 deacetylate K310 to attenuate NF-κB activity; resveratrol-mediated SIRT1 activation reduces NF-κB output via K310 deacetylation
• •K221 (CBP): Promotes DNA binding by reducing IκBα re-association

Methylation:

• •K218/K221 (NSD1): Di-methylation promotes DNA binding
• •K314/K315 (SET9/SETD7): Monomethylation targets RelA for proteasomal degradation

Ubiquitination:

• •K48-linked (SOCS1, PDLIM2, COMMD1): Proteasomal degradation of nuclear RelA to terminate signaling
• •K63-linked: Stabilizing or activating modifications at specific sites

---

Crosstalk with Other Signaling Pathways

NF-κB/TGF-β: TAK1 is shared — TGF-β receptors activate TAK1 which phosphorylates IKKβ, providing a direct link between TGF-β and NF-κB in inflammatory and fibrotic contexts. In cancer, NF-κB-driven TGFB1 transcription can create paracrine immunosuppressive loops.

NF-κB/JAK-STAT: IL-6 transcribed by NF-κB acts in autocrine/paracrine fashion on IL-6R/gp130 to activate JAK1/2-STAT3; nuclear STAT3 and RelA physically interact and co-occupy many target gene promoters, creating a feedforward inflammatory amplifier. In multiple myeloma, constitutive IL-6/STAT3 and NF-κB cooperate to drive tumor cell survival.

NF-κB/HIF-1α: NF-κB directly transactivates HIF1A under normoxia via κB sites in the HIF1A promoter; conversely, HIF-1α enhances NF-κB target gene expression at hypoxic inflammatory sites. This crosstalk amplifies inflammatory gene expression in ischemic tissues and tumors.

NF-κB/p53: NF-κB and p53 mutually antagonize each other; RelA competes with p53 for limiting CBP/p300 co-activator; in cancer cells with constitutive NF-κB, p53 transcriptional activity is frequently attenuated even without p53 mutation.

NF-κB/Notch: NICD (Notch intracellular domain) physically associates with IKKα and activates non-canonical NF-κB; conversely, NF-κB drives JAG1 transcription to sustain Notch pathway activation in cancer stem cells.

---

Research Tools and Pharmacological Probes

---

Experimental Protocols for Research Applications

Protocol 1: TNFα-Induced IκBα Degradation and RelA Nuclear Translocation

Objective: Characterize canonical NF-κB activation kinetics — IκBα phosphorylation, degradation, and nuclear RelA accumulation.

Materials: Recombinant TNFα (carrier-free), Bay 11-7082 or BMS-345541, pIκBα (S32/S36) antibody (Cell Signaling #2859), total IκBα antibody (Cell Signaling #4812), anti-RelA/p65 (Cell Signaling #8242), anti-lamin B1 (nuclear fraction marker), anti-GAPDH (cytoplasmic marker), nuclear/cytoplasmic fractionation kit.

Procedure:

1. Starve cells for 4 h in serum-reduced medium (1% FBS) to synchronize basal NF-κB state

2. Pre-treat ± 10 µM Bay 11-7082 for 30 min as IKK inhibitor control

3. Stimulate with 10 ng/mL TNFα for 0, 5, 10, 15, 30, 60, 120 min

4. Whole-cell lysates (WCL): Probe for pIκBα (S32/S36) — appears within 5 min; IκBα total — degrades by 10–15 min then resynthesizes by 30–60 min; RelA — remains constant

5. Nuclear/cytoplasmic fractionation at 15 min: Probe nuclear fraction for RelA (peak at 15–20 min), lamin B1 (loading control); cytoplasmic fraction for IκBα, GAPDH

6. Quantify bands; express IκBα as % of 0-min control; nuclear/cytoplasmic RelA ratio

Expected result: pIκBα appears at 5 min; total IκBα falls to <20% by 15 min; nuclear RelA increases 3–10-fold by 15 min; IκBα resynthesizes by 30–60 min; Bay 11-7082 pre-treatment blocks pIκBα and IκBα degradation, confirming IKK dependence.

---

Protocol 2: NF-κB Luciferase Reporter Assay — Dose-Response and Inhibitor Profiling

Objective: Quantify NF-κB transcriptional activation and characterize inhibitor potency (IC50).

Materials: NF-κB-Luc reporter plasmid (5× κB consensus sites, e.g., Cignal NF-κB Reporter), pRL-TK Renilla control, Lipofectamine 3000, TNFα, LPS (TLR4 agonist), IL-1β, test inhibitors (Bay 11-7082, BMS-345541, MLN4924, MG-132), Dual-Luciferase Reporter Assay System.

Procedure:

1. Transfect cells with NF-κB-Luc + pRL-TK (50:1 ratio) 24 h pre-experiment

2. Pre-treat with inhibitor serial dilutions (8-point, 3-fold dilution, top 30 µM) for 1 h

3. Stimulate with TNFα (1–10 ng/mL), LPS (100 ng/mL), or IL-1β (1 ng/mL) for 6 h

4. Lyse; measure dual luciferase; normalize firefly/Renilla; calculate fold-induction and IC50

5. Compare agonists: TNFα (rapid, TNFR-TRADD-RIPK1-IKK); LPS (slower, TLR4-MyD88/TRIF-TRAF6-TAK1-IKK); IL-1β (intermediate, IL-1R-MyD88-IRAK4-TRAF6-TAK1-IKK)

Expected result: TNFα induces 20–100-fold NF-κB reporter (cell-type dependent); Bay 11-7082 IC50 ~3–10 µM; BMS-345541 IC50 ~1–5 µM; MLN4924 IC50 ~0.3–1 µM (via cullin neddylation inhibition → β-TrCP inactivation → IκBα accumulation). Proteasome inhibitors (MG-132, bortezomib) may paradoxically increase or maintain basal NF-κB reporter (due to IκBα resynthesis also blocked, though nuclear NF-κB cleared by proteasome) — confirm with nuclear p65 Western.

---

Protocol 3: Electrophoretic Mobility Shift Assay (EMSA) for NF-κB DNA Binding

Objective: Directly detect NF-κB:DNA complexes in nuclear extracts.

Materials: Nuclear extraction kit, IRDye-700 or 32P-labeled κB consensus probe (5'-AGTTGAGGGGACTTTCCCAGGC-3' / complement), anti-RelA for supershift, anti-p50 for supershift, competitor unlabeled probe, mutant κB probe control, LiCor Odyssey or PhosphorImager.

Procedure:

1. Prepare nuclear extracts (NE) at each time point post-TNFα stimulation (0, 15, 30, 60 min)

2. Binding reaction: 5 µg NE + labeled probe (0.1 pmol) + poly-dIdC (non-specific competitor) + binding buffer (10 mM Tris pH 7.5, 50 mM NaCl, 1 mM DTT, 5% glycerol, 1 mM MgCl₂) at RT for 20 min

3. Supershift controls: add 1 µg anti-RelA or anti-p50 to NE 30 min before probe addition

4. Specificity controls: 100× molar excess unlabeled κB probe (specific competitor) or mutant probe (non-specific competitor)

5. Run 5% non-denaturing PAGE (0.5× TBE buffer, pre-run 30 min, 200V at 4°C) for 2–3 h

6. Transfer to nylon membrane; image on LiCor (IRDye) or expose to PhosphorImager (32P)

Expected result: Unstimulated NE shows faint or no complex; 15–30 min post-TNFα shows strong retarded complex (RelA/p50 dimer); anti-RelA supershift shifts the band further; 100× cold κB probe abolishes the complex; mutant probe has no effect. Two complexes often visible: faster (p50/p50) and slower (RelA/p50).

---

Protocol 4: NF-κB p65 Nuclear Translocation by High-Content Imaging

Objective: Quantify NF-κB activation in individual cells by automated imaging of p65 nuclear translocation.

Materials: Cells in 96-well optical-bottom plates (CellCarrier, PerkinElmer), anti-p65/RelA (Cell Signaling #8242 or BD Biosciences #610869), DAPI, fluorescent secondary (Alexa Fluor 488 anti-rabbit), Operetta or ImageXpress high-content microscope, CellProfiler or Harmony analysis software.

Procedure:

1. Treat cells in 96-well plate with TNFα dose range (0.003–30 ng/mL) ± inhibitor pre-treatments for 30 min

2. Fix with 4% PFA, 15 min RT; permeabilize 0.1% Triton X-100, 10 min; block 3% BSA, 30 min

3. Anti-p65 (1:400) overnight 4°C; Alexa Fluor 488 secondary + DAPI 1 h RT

4. Image with 20× objective: 4 fields/well, FITC (p65) and DAPI channels

5. CellProfiler pipeline: identify nuclei (DAPI); define cytoplasm annulus (expand 5–10 px from nucleus edge); measure mean p65 intensity in nucleus vs. cytoplasm

6. Report: nuclear/cytoplasmic p65 ratio per cell; population mean ± SD

Expected result: TNFα EC50 for p65 nuclear translocation ~0.1–1 ng/mL; maximum nuclear/cytoplasmic ratio 3–10-fold over vehicle; IKKβ inhibitors shift EC50 rightward; Z-factor >0.5 for 96-well format validates assay for screen application.

---

Protocol 5: Reconstituting NF-κB Oscillations — Live-Cell Imaging with RelA-GFP

Objective: Visualize single-cell NF-κB nuclear oscillations in response to TNFα stimulation.

Materials: Cell line stably expressing RelA-GFP (or use MEF RelA-GFP knock-in where available), spinning-disk or epifluorescence microscope with environmental chamber (37°C/5% CO₂), microfluidics or superfusion system for ligand delivery during imaging, ImageJ/Fiji for nuclear tracking.

Procedure:

1. Seed cells on 35-mm glass-bottom dishes; equilibrate in environmental chamber 30–60 min

2. Acquire baseline (DAPI-free; track GFP): 5 min intervals for 10 min pre-stimulation

3. Apply TNFα (2–10 ng/mL) by superfusion or direct addition without disturbing focal plane

4. Image every 2–5 min for 3–8 h; 63× oil objective, 300–500 ms exposure

5. Track nuclear GFP intensity per cell using nuclear segmentation (Fiji: Analyze Particles on brightfield or H2B-RFP co-marker)

6. Plot nuclear RelA-GFP intensity vs. time per cell; identify oscillation frequency and amplitude; assess cell-to-cell heterogeneity

---

Disease Contexts

Multiple Myeloma

Multiple myeloma (MM) is the prototypical NF-κB-dependent cancer: ~85% of primary MM tumors show constitutive NF-κB activation via canonical or non-canonical mutations. Canonical pathway activators include TRAF2 deletion, CYLD mutation, cIAP1/2 deletion, and CD40 gain-of-function; non-canonical activators include TRAF3 deletion, NIK amplification, and BIRC2/3 deletions that stabilize NIK. Bortezomib (proteasome inhibitor, stabilizes IκBα) and carfilzomib are first-line MM therapies; their efficacy is partly attributed to NF-κB blockade, though ER stress induction is an additional mechanism. Research models include H929, RPMI-8226, and U266 MM cell lines.

Diffuse Large B-Cell Lymphoma (DLBCL)

The activated B-cell (ABC) subtype of DLBCL is defined by constitutive NF-κB activity driven by BCR/CARD11-BCL10-MALT1 signaling; CARD11 gain-of-function mutations (L251P, M362I) bypass antigen receptor requirement. MYD88 L265P mutation (present in ~30% ABC-DLBCL) activates IRAK4/NF-κB; CD79B mutations activate BCR signaling. MALT1 protease inhibitors are in research development; IRAK4 inhibitors are in clinical trials for MYD88-mutant lymphomas.

Inflammatory Bowel Disease (IBD)

NF-κB activity in intestinal epithelial cells (IECs) and lamina propria macrophages is elevated in active Crohn's disease and ulcerative colitis. IEC-specific IKKβ knockout mice show exacerbated DSS colitis (NF-κB protects IECs from apoptosis), while macrophage IKKβ deletion reduces TNF/IL-6 production and ameliorates colitis — illustrating cell-type-specific NF-κB functions. NF-κB-blocking strategies (antisense oligonucleotides to IκBα mRNA, NF-κB decoy oligonucleotides) have been explored in IBD research models.

Sepsis

LPS-induced TLR4 → MyD88 → TRAF6 → TAK1 → IKKβ → NF-κB drives the TNF/IL-6/IL-1β cytokine storm of sepsis. While NF-κB blockade reduces cytokine production in LPS-challenge models, NF-κB is also required for neutrophil and macrophage bactericidal function — complete inhibition impairs pathogen clearance. Research in sepsis models focuses on temporally controlled or cell-selective NF-κB modulation.

---

Literature References

1. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol. 2005;7(8):758-765. PMID: 16056267

2. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IκB-NF-κB signaling module: temporal control and selective gene activation. Science. 2002;298(5596):1241-1245. PMID: 12424381

3. Tay S, Hughey JJ, Lee TK, et al. Single-cell NF-κB dynamics reveal digital activation and analogue information processing. Nature. 2010;466(7303):267-271. PMID: 20581820

4. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26(3):203-234. PMID: 22302935

5. Sun SC. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545-558. PMID: 28580957

7. Karin M, Greten FR. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-759. PMID: 16175180

10. Ghosh S, Hayden MS. New regulators of NF-κB in inflammation. Nat Rev Immunol. 2008;8(11):837-848. PMID: 18927578

11. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;2006(357):re13. PMID: 17047224

12. Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature. 2009;458(7237):430-437. PMID: 19325622

13. Shih VF, Tsui R, Caldwell A, Hoffmann A. A single NFκB system for both canonical and non-canonical signaling. Cell Res. 2011;21(1):86-102. PMID: 21187856

---

For Research Use Only. This content describes experimental research reagents and signaling pathway mechanisms for in vitro laboratory investigation. Not intended for use in humans or animals.